Antibody Solutions Licenses STR from mAbsolve

Antibody Solutions have licensed our STR technology to provide their clients with access to this cutting edge technology ...
Read More

mAbsolve to exhibit at Festival of Biologics 2023

mAbsolve will be exhibiting at the Festival of Biologics in Basel on the 10-12th of October. We will ...
Read More

MHRA Licenses Novel Fc Silencing Technology from mAbsolve

The Medical and Healthcare products Regulatory Agency (MHRA) has licensed mAbsolves novel Fc silencing technology to produce gold ...
Read More

STR technology available for antibodies generated from OmniAb platform

OmniAb have entered into a licensing agreement for STR. The agreement provides OmniAb with exclusive, sublicensable access to ...
Read More

Geoff Hale confirmed as keynote speaker at AET 2023

Our CEO, Geoff Hale, has been confirmed as a keynote speaker at Antibody Engineering and Therapeutics 2023 in ...
Read More

Use of STR in an Fc fusion protein being developed for COVID-19 published

Dr. Neil Bodie and colleagues at Paradigm Immunotherapeutics along with collaborators at Kyoto University and Michigan State University ...
Read More

Genscript ProBio licences STR technology from mAbsolve

Genscript ProBio have licenced mAbsolves first in class solution for abolising antibody effector function to enable their worldwide ...
Read More

Geoff Hale to present at Promega Biologics Symposium

On Thursday 22nd September, our CEO, Geoff Hale, will be presenting some of our recent work on the ...
Read More

mAbsolve publish paper in mAbs

Today our CEO and CSO, Geoff Hale and Ian Wilkinson, have had a new article published in mAbs. ...
Read More